Seres Therapeutics, Inc. (MCRB) Earnings History
Annual and quarterly earnings data from 2012 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | 100.0% | -44.5% | -45.2% |
| 2020 | -172.7% | -265.3% | -268.3% |
Download Data
Export MCRB earnings history in CSV or JSON format
Free sign-in required to download data
Seres Therapeutics, Inc. (MCRB) Earnings Overview
As of March 5, 2026, Seres Therapeutics, Inc. (MCRB) reported trailing twelve-month net income of $5M, reflecting -0.1% year-over-year growth. The company earned $0.61 per diluted share over the past four quarters.
Looking at the long-term picture, MCRB's historical earnings data spans multiple years. The company achieved its highest annual net income of $136,000 in fiscal 2024, representing a new all-time high.
Seres Therapeutics, Inc. maintains positive profitability with. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including PHGE (-$37M net income), ARMP (-$47M net income, -3.7% margin), EVGN (-$3M net income, -1.9% margin), MCRB has comparable earnings metrics. Compare MCRB vs PHGE →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $136,000 | +100.1% | -$121M | $-18.86 | - | - |
| 2023 | -$114M | +54.5% | -$195M | $-17.77 | - | - |
| 2022 | -$250M | -281.5% | -$180M | $-46.29 | - | - |
| 2021 | -$66M | +26.4% | -$64M | $-14.30 | -45.2% | -44.5% |
| 2020 | -$89M | -26.8% | -$88M | $-22.34 | -268.3% | -265.3% |
| 2019 | -$70M | +29.0% | -$72M | $-24.81 | -203.7% | -208.3% |
| 2018 | -$99M | -10.7% | -$100M | $-48.57 | -350.0% | -354.8% |
| 2017 | -$89M | +2.4% | -$91M | $-44.19 | -278.4% | -284.7% |
| 2016 | -$92M | -67.2% | -$93M | $-46.00 | -420.7% | -426.5% |
| 2015 | -$55M | -227.8% | -$55M | $-46.60 | - | - |
See MCRB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MCRB Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare MCRB vs LLY
See how MCRB stacks up against sector leader Eli Lilly and Company.
Start ComparisonFrequently Asked Questions
Is MCRB growing earnings?
MCRB EPS of $0.61 reflects slowing growth at -0.1%, below the 5-year CAGR of N/A. TTM net income is $5M. Expansion rate has moderated.
What are MCRB's profit margins?
Seres Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are MCRB's earnings?
MCRB earnings data spans 2012-2024. The current earnings trend is -0.1% YoY. Historical data enables comparison across business cycles.